Probiotics face scientific scrutiny amid new insulin-stimulating research

Research into probiotics is revealing a divide between consumer popularity and scientific evidence. Epidemiologist Gideon Meyerowitz-Katz notes that while probiotics are widely marketed for immunity and gut health, large-scale clinical trials often fail to show significant benefits compared to placebos. For instance, major studies regarding diarrhea prevention, eczema, and symptom severity in certain conditions have not yielded conclusive results.

In a separate development, researchers at the Shanghai Academy of Natural Sciences have developed a living probiotic designed to assist with glucose regulation. This biological approach aims to detect rising blood sugar levels and trigger the pancreas to increase insulin secretion. Unlike continuous therapies, this reactive method would only intervene during hyperglycemic episodes. While promising for type 2 diabetes management, the technology requires extensive preclinical and clinical testing to ensure safety and long-term efficacy.